Phase 2 clinical trial

The study suggests a dietary/prebiotic compound (2'-FL) can change gut microbes and patient-reported disease control in mild-to-moderate UC, which could point to non-drug ways to support symptoms and microbiome health.

These development programs could expand treatment choices for Crohn’s disease and may eventually address fibrosis and refractory disease—two major unmet needs. Progress in trials could change management options in coming...

People with Crohn's disease who develop symptomatic intestinal strictures currently often need endoscopic dilation or surgery. This trial tests an investigational oral drug (ontunisertib) aiming to improve...

A pediatric Phase 2 trial testing etrasimod could expand treatment options for children with moderately to severely active ulcerative colitis if later shown safe and effective. Families of affected children and their...

Early-phase mechanistic trials test how a new drug affects disease biology and safety; results can help decide whether larger trials should follow.

Dietary components and processed vegetarian/vegan products may alter the gut microbiome and intestinal barrier — both are relevant to IBD. This study will directly compare common vegan products and meat substitutes with...

The study will test whether routine point‑of‑care intestinal ultrasound changes clinical decisions compared with standard monitoring, which could make monitoring less invasive and more responsive if effective.

The trial could show whether a smart-label app plus clinician alerts improves medication adherence and downstream clinical outcomes for people with Crohn's disease or ulcerative colitis starting oral or subcutaneous...

An expanded access program can allow people with Crohn's disease or ulcerative colitis to access upadacitinib before local approval when no other suitable treatments exist.

The study tests a new mechanism (TL1A inhibition) that may reduce inflammation and fibrosis in IBD. Positive phase 2b results suggest duvakitug could become another treatment option if later trials confirm benefit and...

This article summarizes positive phase IIb trial results for duvakitug (anti‑TL1A) in moderate‑to‑severe Crohn’s disease and ulcerative colitis, which could lead to a new targeted treatment option if later phase trials...

Depression is common in people with IBD and can worsen quality of life and disease outcomes. This trial explores whether mirtazapine—an antidepressant thought to have favorable gastrointestinal tolerability—can be...

New phase IIb trial results suggest an anti‑TL1A antibody (duvakitug) produced measurable benefit in both Crohn’s disease and ulcerative colitis, which could lead to a new treatment option if later phase III trials...

Patients and clinicians interested in Crohn’s disease should note a new company (Fibrx) is prioritizing drugs that directly target fibrosis and strictures — an area with few medical options today.

A new oral investigational therapy (TAK-279) is being tested in a randomized phase 2 trial for moderate–severe ulcerative colitis. Trial results could influence future treatment options if the drug proves safe and...

This pilot tests whether some patients with acute severe ulcerative colitis could avoid hospitalization by using early oral JAK inhibitor therapy plus steroids with close remote monitoring — a change that could reduce...

Patients and clinicians often want to know how quickly symptoms improve after starting a biologic. This study is designed to compare early patient‑reported symptom changes after starting vedolizumab versus IL‑23...

This registry will track how people with moderate to severe ulcerative colitis do on risankizumab in routine Japanese clinical practice, which may provide information about real-world remission rates and longer-term...

A new Phase 2 trial is testing SL-325 given IV for moderate-to-severe Crohn's disease with endoscopic response as the primary outcome. The study targets people who have not responded to or cannot tolerate several...

The study tests whether combining a standardized coping-skills program with biologic therapy improves emotional well-being and clinical/endoscopic outcomes in people with early Crohn's disease—addressing common...

Shattuck Labs plans to advance a DR3-targeting bispecific antibody (SL-325) into a Phase 2b trial for Crohn's disease, which is relevant to people watching new investigational biologics for IBD. The report is a...

If PALI-2108 proves safe and effective in Phase 2 trials, it could add a new oral treatment option for people with ulcerative colitis and Crohn’s disease. Early Phase 1 signals and a funded Phase 2 program mean the...

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from t.co.

Cure8 could only read part of this source from grafa.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials.

AI models that combine CTE/MRE imaging with clinical and molecular data could improve objective classification of small-bowel Crohn's disease and help predict which patients are likely to respond to medical therapy...

If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...

This filing reports that PALI‑2108, an investigational oral PDE4 prodrug for IBD, showed encouraging Phase 1 signals and is moving into Phase 2 trials — a step toward more definitive efficacy data. The company also...

This trial tests a new oral drug, AC-101, for moderate-to-severe ulcerative colitis and may expand future treatment options if it proves effective and safe. The study targets patients who have failed or could not...

Real-world PSP registries can show how long people stay on vedolizumab and how it’s used alongside or compared with other advanced therapies like tofacitinib. That information can help patients and clinicians understand...

Many people with Crohn’s disease have ongoing inflammation despite stable medication. If dietary personalization can reduce inflammation, it could offer a nonpharmacologic add-on to help bridge gaps without immediate...

TL1A-blocking antibodies have shown promising response rates in early trials for both Crohn's disease and ulcerative colitis. Understanding TL1A biology could help match new therapies to the patients most likely to...

A new Phase 2 trial is testing whether intravenous allogeneic HB-adMSCs can improve Crohn’s symptoms and intestinal inflammation. If effective and safe, the therapy could offer a different mechanism of treatment from...

A new investigational drug (BI 3032950) is being tested specifically for people with ulcerative colitis who did not do well on prior biologic or targeted treatments. If effective and safe, it could become another option...

This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.

New drugs in mid-stage trials may expand treatment options for people with moderate to severe Crohn's disease, especially those who have not responded to existing therapies. This trial is measuring clinical remission at...

New leadership hires and a planned Phase 2 program mean prifemilast — an oral PDE4B-selective investigational drug — is moving toward larger IBD studies. People with IBD who want more oral treatment options or who follow...

This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...

The oral microbiome in children with Crohn's disease appears to reflect disease severity and changes with treatment, suggesting a potential noninvasive biomarker for monitoring response to nutritional therapies like CDED...

This registered Phase 2 trial tests guselkumab, golimumab, and a new investigational agent (JNJ-78934804) in adults with moderate–severe ulcerative colitis who previously failed advanced therapies. Results could affect...

Long-term safety data on biologics and thiopurines are important for people with ulcerative colitis because they help patients and clinicians weigh risks (including malignancies and pregnancy-related outcomes) when...

This registry will collect one-year, patient-reported outcomes on symptom control and clinical remission while people with IBD receive Zymfentra (infliximab-dyyb) in routine care — information that may help patients and...

Real-world data may help show how guselkumab performs in routine clinical practice for adults with moderate-to-severe UC who haven’t had prior biologics, information that could be useful to patients and clinicians...

New oral therapies in Phase 2/3 could expand treatment options for adults with moderate–severe Crohn's disease, including those who are naïve to advanced therapies or who failed prior biologics.

This trial tests whether pomegranate juice can lower fecal calprotectin, a commonly used marker of intestinal inflammation, in people with IBD in remission. If effective, such a dietary approach could be of interest to...

The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...

If sodium intake influences gut proteolytic activity, microbiota and inflammation, the findings could help tailor dietary guidance and personalized nutrition strategies for people with Crohn’s disease.

A Phase 2/3 trial of guselkumab could expand biologic treatment options for people with moderate to severe ulcerative colitis if efficacy and safety are demonstrated. The trial’s use of standard clinical endpoints...

Anti-drug antibodies can make anti-TNF biologics stop working for people with Crohn’s disease. This trial tests a simple, short antibiotic course given before starting anti-TNF therapy to see if it lowers antibody...